膀胱癌靶向治疗的现状

The status quo of targeted therapy in bladder cancer

膀胱癌是我国泌尿系统最常见的恶性肿瘤。晚期或转移的膀胱尿路上皮癌的预后通常较差,一线的治疗方式为以铂类为基础的联合化疗,但是有超过一半的患者因肾功能不全、恶病质或其他并发症而不能耐受这类治疗。随着靶向药物在肿瘤治疗中大放异彩,膀胱癌的靶向治疗也进入了临床研究中。文章对人表皮生长因子家族、血管内皮生长因子及受体、成纤维细胞生长因子受体、磷脂肌醇3激酶-蛋白激酶B-雷帕霉素靶蛋白等膀胱癌靶向治疗的研究进展进行综述。

Bladder cancer is the most common malignant tumor of the urinary system. Prognosis of advanced or metastatic bladder urothelial carcinoma is usually poor. More than half of the patients cannot receive standard,first-line cisplatin-based chemotherapy due to renal dysfunction,cachexia or other complications. As targeted drugs shine in cancer treatment,targeted therapy for bladder cancer has also entered clinical research. This article reviews the targeted therapies include human epithelial growth factor family, vascular endothelial growth factor and receptor,fibroblast growth factor receptor,phosphoinositide 3-kinase-AKT-mammalian target of rapamycin.